论文部分内容阅读
目的探讨表柔比星联合紫杉醇治疗三阴性乳腺癌的临床效果。方法 50例三阴性乳腺癌患者,依照随机抽签原则分为治疗组和对照组,各25例。治疗组应用表柔比星联合紫杉醇治疗,对照组单独应用表柔比星治疗。对比两组患者的治疗效果与治疗前后肿瘤直径变化。结果治疗组患者中完全缓解10例,部分缓解11例,稳定3例,进展1例,治疗有效率为84.0%(21/25);对照组中完全缓解4例,部分缓解10例,稳定7例,进展4例,治疗有效率为56.0%(14/25);两组治疗有效率对比差异具有统计学意义(P<0.05)。治疗后,治疗组肿瘤直径为(1.9±0.6)cm,对照组肿瘤直径为(3.2±0.7)cm,对比差异有统计学意义(t=7.050,P=0.000<0.05)。结论表柔比星联合紫杉醇治疗三阴性乳腺癌的临床效果确切,能有效缩小肿瘤组织,可作为三阴性乳腺癌患者理想用药方案。
Objective To investigate the clinical effect of epirubicin combined with paclitaxel in the treatment of triple negative breast cancer. Methods 50 patients with triple-negative breast cancer were divided into treatment group and control group according to the principle of random drawing, 25 patients in each group. The treatment group was treated with epirubicin combined with paclitaxel, and the control group was treated with epirubicin alone. The treatment effect of the two groups of patients was compared with the change of tumor diameter before and after treatment. Results In the treatment group, there were 10 patients with complete remission, 11 patients with partial remission, 3 patients with stable, 1 patient progressing, and the effective rate of treatment was 84.0% (21/25). In the control group, 4 patients were completely relieved, 10 patients partially relieved, and 7 were stable. Cases, progress in 4 cases, the effective rate of treatment was 56.0% (14/25); the difference in treatment efficacy between the two groups was statistically significant (P<0.05). After treatment, the tumor diameter in the treatment group was (1.9±0.6) cm, and the tumor diameter in the control group was (3.2±0.7) cm. The difference was statistically significant (t=7.050, P=0.000<0.05). Conclusion Epirubicin combined with paclitaxel has a definite clinical effect in the treatment of triple-negative breast cancer. It can effectively reduce the tumor tissue and can be used as an ideal drug for triple-negative breast cancer patients.